Marco V. Haselager

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

Marco V. Haselager, Karoline Kielbassa, Johanna ter Burg et al. · Blood · 2020 · 111 citations · Full text

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL

Marco V. Haselager, Rachel Thijssen, Christopher M. West et al. · Cell Death and Differentiation · 2021 · 82 citations · Full text

Non-canonical Nf-κb, Chronic Lymphocytic Leukemia, Apoptosis +23

<scp>JAK–STAT</scp> signalling shapes the <scp>NF‐κB</scp> response in <scp>CLL</scp> towards venetoclax sensitivity or resistance via <scp>Bcl‐XL</scp>

Marco V. Haselager, Rachel Thijssen, Danique Bax et al. · Molecular Oncology · 2022 · 25 citations · Full text

Adaptive Immune System, Immune Regulation, Immunology +24

In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival

Marco V. Haselager, Bianca F. van Driel, Eduard Perelaer et al. · HemaSphere · 2023 · 22 citations · Full text

Cll Proliferation, Lymphoid Neoplasia, Vitro 3D +13

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

Karoline Kielbassa, Marco V. Haselager, Danique Bax et al. · Leukemia · 2023 · 19 citations · Full text